MAGE-F1 Inhibitors
Chemical inhibitors of MAGE-F1 predominantly function through the modulation of epigenetic mechanisms, specifically targeting histone deacetylases (HDACs). Trichostatin A, Suberoylanilide Hydroxamic Acid, Romidepsin, Panobinostat, Belinostat, MS-275, Mocetinostat, Valproic Acid, Sodium Butyrate, JNJ-26481585, Mocetinostat, and SB939 are all HDAC inhibitors that influence the expression of MAGE-F1 by altering chromatin remodeling and gene expression patterns. These chemicals inhibit HDACs, leading to changes in the chromatin structure, which in turn affects the expression of genes like MAGE-F1. This inhibition is particularly significant in cancer cells, where MAGE-F1 is often abnormally expressed due to dysregulated epigenetic mechanisms. For instance, Trichostatin A and Suberoylanilide Hydroxamic Acid alter the chromatin state, thereby inhibiting MAGE-F1 expression in tumor cells. Romidepsin and Panobinostat exhibit a similar mechanism, targeting HDACs to influence the chromatin structure and consequently suppress MAGE-F1 expression.
Moreover, Belinostat and MS-275 exert their inhibitory effects on MAGE-F1 by impacting chromatin remodeling, leading to altered gene expression in cancer cells where MAGE-F1 is aberrantly expressed. Mocetinostat, an isotype-specific HDAC inhibitor, and Valproic Acid, a short-chain fatty acid HDAC inhibitor, also contribute to the inhibition of MAGE-F1 by affecting chromatin structure and gene expression. Sodium Butyrate's action as an HDAC inhibitor suppresses MAGE-F1 expression, particularly in tumor cells, by influencing chromatin remodeling. Similarly, JNJ-26481585, Mocetinostat, and SB939, by inhibiting HDACs, can change the epigenetic landscape in cancer cells, leading to the inhibition of MAGE-F1 expression. These chemicals, through their specific actions on HDACs and subsequent effects on chromatin structure and gene expression, collectively contribute to the inhibition of MAGE-F1, especially in the context of its dysregulated expression in cancer cells.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A inhibits histone deacetylases (HDACs), affecting chromatin remodeling and gene expression. MAGE-F1 is a cancer/testis antigen, and its expression is modulated by epigenetic mechanisms. By inhibiting HDACs, Trichostatin A can alter the epigenetic state, leading to the inhibition of MAGE-F1 expression in cancer cells. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid, another HDAC inhibitor, impacts gene expression by altering chromatin structure. Since MAGE-F1 is regulated epigenetically, Suberoylanilide Hydroxamic Acid's action on HDACs can result in the inhibition of MAGE-F1 expression, particularly in tumor cells where it's abnormally expressed. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $214.00 $622.00 | 1 | |
Romidepsin is an HDAC inhibitor that modulates chromatin remodeling, influencing gene expression patterns. By targeting HDACs, Romidepsin can inhibit the expression of MAGE-F1, particularly in cancer cells where epigenetic regulation is often disrupted. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $196.00 | 9 | |
Panobinostat is a broad-spectrum HDAC inhibitor. It alters gene expression by affecting chromatin structure. In the context of MAGE-F1, Panobinostat can inhibit its expression by modulating the epigenetic landscape, particularly in tumor cells. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $153.00 $561.00 | ||
Belinostat, an HDAC inhibitor, affects chromatin remodeling and gene expression. It can inhibit MAGE-F1 by altering the epigenetic regulation of its expression, particularly in cancer cells where MAGE-F1 is aberrantly expressed. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $88.00 $208.00 | 24 | |
MS-275, an HDAC inhibitor, modulates gene expression via chromatin remodeling. This can lead to the inhibition of MAGE-F1 expression, particularly in tumor environments where epigenetic mechanisms are often altered. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $210.00 $242.00 $1434.00 | 2 | |
Mocetinostat, an isotype-specific HDAC inhibitor, influences gene expression by affecting chromatin structure. This can result in the inhibition of MAGE-F1 expression, especially in cancer cells where epigenetic regulation plays a significant role. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $85.00 | 9 | |
Valproic Acid, a short-chain fatty acid and HDAC inhibitor, affects chromatin remodeling and gene expression. By inhibiting HDACs, it can lead to the inhibition of MAGE-F1, particularly in cancer cells where its expression is regulated epigenetically. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
Sodium Butyrate, an HDAC inhibitor, influences gene expression patterns through chromatin remodeling. Its inhibition of HDACs can lead to the suppression of MAGE-F1 expression, particularly in tumor cells where MAGE-F1 is abnormally expressed. | ||||||
JNJ-26481585 | 875320-29-9 | sc-364515 sc-364515A | 5 mg 50 mg | $321.00 $1224.00 | ||
JNJ-26481585, a potent HDAC inhibitor, alters gene expression by impacting chromatin structure. This can inhibit MAGE-F1 expression by changing the epigenetic state, particularly in cancer cells where its expression is dysregulated. | ||||||